Therefore, the investigation into PsEV content revealed significant alterations in key markers associated with AD pathology, viz., amyloid-β (1–42) and p-Tau, which are a well-established marker of AD and exhibit an elevated level in PsEVs from AD and MCI patients compared to AMC in our study. The gene discussed is MAPT; the disease is Alzheimer disease.